 | Ales Linhart |
Prominent publications by Ales Linhart
BACKGROUND: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore ...
| Also Ranks for: Odyssey Outcomes | coronary syndrome | patients alirocumab | controlled trial | primary endpoint |
AIMS: The 2019 report from the European Society of Cardiology (ESC) Atlas provides a contemporary analysis of cardiovascular disease (CVD) statistics across 56 member countries, with particular emphasis on international inequalities in disease burden and healthcare delivery together with estimates of progress towards meeting 2025 World Health Organization (WHO) non-communicable disease targets.
METHODS AND RESULTS: In this report, contemporary CVD statistics are presented for member ...
| Also Ranks for: European Society | cardiovascular disease | income countries | obesity diabetes | esc member |
BACKGROUND: Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients.
METHODS: The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. ...
| Also Ranks for: Heart Failure | patients hyperuricemia | uric acid | allopurinol treatment | atrial fibrillation |
| Also Ranks for: Pericardial Diseases | 2015 esc guidelines | diagnosis management | chronic disease | heart injuries |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
[ PUBLICATION ]
BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.
OBJECTIVES: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute ...
| Also Ranks for: Cardiovascular Outcomes | acute coronary | statin treatment | mace ldlc | 9 inhibition |
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
[ PUBLICATION ]
OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.
RESEARCH DESIGN AND METHODS: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients ...
| Also Ranks for: 2 Diabetes | levels lipoproteina | acute coronary syndrome | proprotein convertase | therapies reduce |
Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable
[ PUBLICATION ]
| Also Ranks for: Cardiopatía Isquémica | práctica clínica | diagnóstico tratamiento |
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome
[ PUBLICATION ]
Importance: Inflammation promotes cardiovascular disease and anti-inflammatory treatment reduces cardiovascular events in patients with chronic coronary syndrome. Chronic kidney disease (CKD) is a risk factor for cardiovascular disease. It is unclear how inflammation mediated by interleukin 6 (IL-6) in patients with CKD is linked to cardiovascular disease.
Objective: To investigate associations between IL-6 and cardiovascular outcomes in patients with chronic coronary syndrome in ...
| Also Ranks for: Cardiovascular Disease | hazard ratio | interquartile range | 157 95 | multicenter cohort |
| Also Ranks for: Enfermedad Cardiovascular |
Key People For Cardiovascular Outcomes
Ales Linhart:Expert Impact
Concepts for whichAles Linharthas direct influence:Cardiovascular outcomes, Coronary syndrome, Odyssey outcomes, Alirocumab treatment, Acute coronary syndrome, European society, Cardiovascular disease, Patients alirocumab.
Ales Linhart:KOL impact
Concepts related to the work of other authors for whichfor which Ales Linhart has influence:Pericardial effusion, Recurrent pericarditis, Cardiac tamponade, Cardiovascular disease, Chest pain, European society, Acute coronary syndrome.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |